Draft Guidance for Industry; Availability: Oversight of Clinical Investigations; A Risk-Based Approach to Monitoring
Title: NN comments on Draft Guidance on Risk Based Trial Monitoring
Novo Nordisk Inc. - Comment
This is comment on Notice
Draft Guidance for Industry; Availability: Oversight of Clinical Investigations; A Risk-Based Approach to Monitoring
View Comment
Attachments:
NN comments on Draft Guidance on Risk Based Trial Monitoring
Title:
NN comments on Draft Guidance on Risk Based Trial Monitoring
Related Comments
View AllPublic Submission Posted: 09/29/2011 ID: FDA-2011-D-0597-0004
Nov 28,2011 11:59 PM ET
Public Submission Posted: 11/14/2011 ID: FDA-2011-D-0597-0008
Nov 28,2011 11:59 PM ET
Public Submission Posted: 11/14/2011 ID: FDA-2011-D-0597-0011
Nov 28,2011 11:59 PM ET
Public Submission Posted: 11/14/2011 ID: FDA-2011-D-0597-0014
Nov 28,2011 11:59 PM ET
Public Submission Posted: 12/05/2011 ID: FDA-2011-D-0597-0016
Nov 28,2011 11:59 PM ET